Menu
Back to User profile » Dr Antonio Anzueto
Papers published by Dr Antonio Anzueto:
Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease
Ohar JA, Ferguson GT, Mahler DA, Drummond MB, Dhand R, Pleasants RA, Anzueto A, Halpin DMG, Price DB, Drescher GS, Hoy HM, Haughney J, Hess MW, Usmani OS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:79-92
Published Date: 6 January 2022
Update on Asthma–COPD Overlap (ACO): A Narrative Review
Mekov E, Nuñez A, Sin DD, Ichinose M, Rhee CK, Maselli DJ, Coté A, Suppli Ulrik C, Maltais F, Anzueto A, Miravitlles M
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1783-1799
Published Date: 17 June 2021
Time To Revise COPD Treatment Algorithm
Matsunaga K, Oishi K, Miravitlles M, Anzueto A
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2229-2234
Published Date: 27 September 2019
A clinical prediction model for hospitalized COPD exacerbations based on “treatable traits”
Yii ACA, Loh CH, Tiew PY, Xu H, Taha AAM, Koh J, Tan J, Lapperre TS, Anzueto A, Tee AKH
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:719-728
Published Date: 27 March 2019
Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
Calverley PMA, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1297-1308
Published Date: 23 April 2018
Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial
Wise RA, Calverley PMA, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:605-616
Published Date: 14 February 2018
Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
Calverley PMA, Tetzlaff K, Dusser D, Wise RA, Mueller A, Metzdorf N, Anzueto A
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3391-3405
Published Date: 29 November 2017
The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials
Eriksson G, Calverley PM, Jenkins CR, Anzueto AR, Make BJ, Lindberg M, Fagerås M, Postma DS
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1457-1468
Published Date: 15 May 2017
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1325-1337
Published Date: 4 May 2017
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:907-922
Published Date: 17 March 2017
Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
Calverley PM, Eriksson G, Jenkins CR, Anzueto AR, Make BJ, Persson A, Fagerås M, Postma DS
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:13-25
Published Date: 19 December 2016
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design
Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1921-1928
Published Date: 17 August 2016
Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
Calverley PM, Postma DS, Anzueto AR, Make BJ, Eriksson G, Peterson S, Jenkins CR
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:381-390
Published Date: 25 February 2016
Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR® trial
Dusser D, Wise RA, Dahl R, Anzueto A, Carter K, Fowler A, Calverley PM
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:133-145
Published Date: 20 January 2016
Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD
Wilson R, Anzueto A, Miravitlles M, Arvis P, Haverstock D, Trajanovic M, Sethi S
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:985-993
Published Date: 2 June 2015
A score to predict short-term risk of COPD exacerbations (SCOPEX)
Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:201-209
Published Date: 27 January 2015
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:813-824
Published Date: 31 July 2014
Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia
Maselli DJ, Fernandez JF, Whong CY, Echevarria K, Nambiar AM, Anzueto A, Restrepo MI
Infection and Drug Resistance 2012, 5:43-51
Published Date: 1 February 2012
A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology
Wilson R, Anzueto A, Miravitlles M, Arvis P, Faragó G, Haverstock D, Trajanovic M, Sethi S
International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:373-383
Published Date: 29 June 2011
Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials
Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S
International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:269-275
Published Date: 9 May 2011